Background: Sarcopenia, the loss of skeletal muscle mass, strength, and function, is common in elderly individuals but
Introduction
Sarcopenia is a syndrome characterized by the loss of skeletal muscle mass, strength, and function that occurs as a consequence of aging (1) . Muscle mass represents a main determinant of muscle strength and has been strongly associated with performance in the activities of daily living and the level of independence in the elderly.
Regular exercise and the regular ingestion of adequate amounts of dietary protein are considered to be 2 major ways to slow the progression of sarcopenia and treat its symptoms (2) .
Resistance training intervention is effective in increasing muscle volume and strength and in improving physical function in older adults (3) (4) (5) . However, exercise training is adopted only by a very small percentage of elderly individuals, possibly because of their frailty. In a systematic review, the benefits of protein supplements on muscle mass and function have been inconsistent (6, 7) . In addition, it is difficult to increase the dietary intake of some elderly participants because of decreased appetite and digestive activity. Thus, a useful intervention for elderly individuals would be to supplement their diet with a small amount of nutrients, which they could easily eat and which would preserve muscle mass and function.
Leucine supplementation, which promotes protein synthesis, has received much attention (8) . In humans, leucine is one of the most potent essential amino acids (EAAs) 6 for the stimulation of muscle protein synthesis (9) . In the elderly, the ingestion of 2.8 g (41%) of leucine but not 1.7 g (26%) of leucine in a total of 6.7 g of EAAs stimulated muscle protein synthesis (10) .
Vitamin D supplementation reduces the risk of falling in older adults when doses of 700-1000 IU/d are used (11) . This beneficial effect on fall reduction separate from exercise prescription seems to occur through action on neuromuscular function (11, 12) . The genomic effect of vitamin D in muscle includes changes in mRNAs that induce de novo protein synthesis that regulates cytoskeletal proteins important for muscle function (13) .
Medium-chain TGs (MCTs) are considered to have the potential for the prevention and treatment of obesity (14, 15) . Medium-chain fatty acids (MCFAs) derived from dietary MCTs enter the mitochondria independently of the carnitine transport system and undergo preferential oxidation (16) . With MCT supplementation, FAs are used substantially for energy production for skeletal muscle. We therefore combined MCTs with leucine-enriched EAAs, which might be used for protein synthesis rather than energy production, and thus might lead to the improvement of muscle function. Indeed, it has been reported that the nitrogen balance of critically ill patients became positive after the administration of MCTs (17) .
We hypothesized that supplementation with a combination of small amounts of leucine-enriched EAAs (40% leucine in 3 g EAAs), cholecalciferol (20 mg, 800 IU), and MCTs (6 g) could achieve a synergistic or additive improvement in skeletal muscle function. We conducted a randomized controlled trial to verify this hypothesis (UMIN000017567).
Methods
Participants. Initial interest in this study was targeted toward all participants who resided in a nursing home and required special care from a helper (n = 65) ( Figure 1 ). Of these, 25 participants were excluded on the basis of the following criteria: a BMI (in kg/m 2 ) >23 (to avoid a further increase in body weight); <65 y of age; received parenteral nutrition; had difficulty swallowing; had severe heart failure or lung, liver, kidney, or blood disease; had a fasting blood glucose concentration of $200 mg/dL, a blood creatinine concentration of $1.5 mg/dL, or a C-reactive protein concentration of $2.0 mg/dL; or had an allergy to the supplements used in the study. The remaining 40 elderly participants agreed to participate in a 3-mo dietary supplement intervention program. However, 2 participants were moved to other facilities before the initiation of the dietary intervention, resulting in a total of 38 participants (11 men and 27 women with a mean 6 SD age of 86.6 6 4.8 y).
The participants and their family members were informed of the nature of the experimental procedures before their written informed consent was obtained. Informed consent from participants with cognitive decline was obtained from their family members (n = 24). The present study was approved by the Human Ethics Committee of Showa WomenÕs University (no. 14-10). The procedures were in accordance with either the ethical standards of the institutional committee on human experimentation or the Helsinki Declaration of 1975 (as revised in 1983). The study took place from September 2014 to December 2014 at the Day Care SKY facility in Yokohama, Japan.
Study design. We performed a 3-mo randomized, controlled, singleblind, parallel group trial in which the 38 participants were randomly allocated to 3 groups (Figure 1 ). Sealed envelopes containing the written informed consent of the individual participants (or their family members) were thoroughly shuffled. Thirteen participants (envelopes) each were allocated to the first and second groups, and 12 participants were allocated to the third group. Allocation was conducted by a person who was not a member of this study.
The first group (n = 13; men, n = 4; women, n = 9; mean age, 85.5 6 3.7 y) received an L-leucine (1.2 g) and cholecalciferol (20 mg)-enriched supplement with 6 g medium-chain TGs (LD + MCT). As an energymatched control to the supplementation of MCTs, the second group (n = 13; men, n = 4; women, n = 9; mean age, 87.7 6 3.9 y) received the same leucine and cholecalciferol-enriched supplement with 6 g long-chain TGs (LCTs) (LD + LCT). The third group (n = 12; men, n = 3; women, n = 9; mean age, 86.8 6 6.5 y) did not receive any supplements (control). The control group did not receive an energy-equivalent placebo because 1) an energy equivalent control for the LD + MCT group was provided as the LD + LCT group, and 2) we wanted to examine whether the addition of a combination of supplements in habitual diets could improve muscle function. We could not create an MCTs-only group because of a limitation in the number of participants.
At baseline and after the 3-mo intervention, the participantsÕ body weight, appendicular muscle mass, strength, function, and cognitive function were assessed, and blood analyses were performed.
Food records for the individual participants were collected every day for 3 mo during the baseline period and for an additional 3 mo during the intervention period. Doctors, nurses, and helpers monitored gastrointestinal and other symptoms, including the defecation state of the participants, every day during the 3-mo intervention period. Exercise protocols that were conducted in the nursing home were not changed between the baseline and intervention periods. Medical drugs (antihypertensive, antiplatelet, antipsychotic, antilipemic, antidiabetic, antiosteoporosis, laxative, and hypnotic drugs) used in some participants were not changed between the baseline and intervention period.
Blinding. The tube containing the supplement was visible to the participants; thus, the participants in the intervention and control groups could not be blinded. However, in the intervention groups, the participants could not distinguish between the supplements in the LD + MCT and LD + LCT.
To assess outcomes, the examiners who oversaw the walking speed test were unaware of each participantÕs group. Other assessments [anthropometric measurements, hand grip strength, knee leg extension time, leg open-and-close test, and peak expiratory flow (PEF) test] were conducted by an expert who had a certificate of training but was aware of the participantÕs group assignment.
Study products. The L-leucine and cholecalciferol-enriched supplement (Amino L40) was purchased from Ajinomoto. One tube (100 g; 30 kcal) of Amino L40 was given at the beginning of dinner. The contents of the tube are listed in Table 1 .
The MCTs and LCTs were provided by the Nisshin OilliO Group, and their FA compositions are shown in Table 2 . Six grams of MCTs (50 kcal; 8.3 kcal/g) or LCTs (54 kcal; 9 kcal/g) per day was mixed with foods such as steamed rice or miso soup at dinnertime. In total, the participants in the intervention groups increased their energy intake by ;80 kcal/d in comparison with the control group. The supplement and oil were given at dinner because the dinner contained much dietary protein relative to that at breakfast and lunch, which may further increase amino acid concentration in the blood, thereby promoting protein synthesis.
Dietary intake. Breakfast, lunch, and dinner were served daily in the nursing care home. The total energy intake of the individual participants was determined by using their estimated basal energy expenditure and physical activity level. Body weight in most of the participants remained constant. A registered dietitian estimated the participantsÕ food intake by weighing leftover food. Snacks eaten during the day and night were also recorded. To estimate the habitual amount of daily intake of energy and nutrients in the individuals at baseline and during the intervention period separately, mean values of the daily energy and nutrient intake of the individual participants for 7 separate days (every 13-15 d) during the 6 Abbreviations used: AC, midupper arm circumference; AMA, midupper arm muscle area; CC, calf circumference; EAA, essential amino acid; LCT, long-chain TG; LD + LCT, L-leucine (1.2 g) and cholecalciferol (20 mg)-enriched supplement with 6 g long-chain TGs; LD + MCT, L-leucine (1.2 g) and cholecalciferol (20 mg)-enriched supplement with 6 g medium-chain TGs; MCFA, medium-chain fatty acid; MCT, medium-chain TG; PEF, peak expiratory flow; PGC-1a, peroxisome proliferator-activated receptor g coactivator 1a; TSF, triceps skinfold thickness.
baseline period and for 7 separate days (every 13-15 d) during the intervention period were calculated by using the Japanese Standard Tables of Food Composition (18) . Then, the means of the daily energy and nutrient intake of the groups were calculated by using these habitual amounts of daily intake of energy and nutrients by the individual ( Table 3) .
Anthropometric analysis. Body weight was measured in the morning at the baseline assessment and after the 3-mo intervention with the use of a digital barrier-free medical scale (AD-6106 W; A&D).
The midupper arm circumference (AC) and bilateral calf circumference (CC) were measured with the use of a flexible nonstretch tape (Inser-Tape; Medical Science Publications). The triceps skinfold thickness (TSF) was measured with the use of a skinfold caliper (Adipometer; Medical Science Publications) according to standard procedure. All AC measurements were performed 3 times on the right and left arms while the participant was sitting, and the median value was adopted. The midupper arm muscle area (AMA) was calculated as follows: (19) . CC was measured with each participant supine, with the left knee raised and the calf at right angles to the thigh. The tape measure was placed around the calf and moved to obtain the maximal circumference. CC could be used to assess muscle mass (20, 21) .
Two participants in the LD + LCT group had right-and left-hand paralysis, respectively, and 1 participant in the control group had left-hand paralysis. These 3 participants were excluded from the analysis of AC, TSF, and AMA ( Figure 1 ). One participant in the LD + MCT group had edema in both legs. Two participants in the LD + LCT group had right-and left-leg paralysis, respectively, and another participant had edema in both legs. One participant in the control group had left-leg paralysis. These 5 participants were excluded from the analysis of CC.
Muscle strength and endurance. Upper extremity strength was measured by hand-grip dynamometry. The maximal voluntary hand grip strength was measured with the use of a digital hand-grip dynamometer (T.K.K. 5401; Takei Kiki Kyogo) with the participant seated on a standard straight-backed chair without armrests. We took 3 measurements for each hand, with a 15-s rest interval, alternating between the dominant and nondominant hands. The maximum value for each hand was adopted.
Two participants in the LD + LCT group had right-and left-hand paralysis, respectively. One participant in the control group had lefthand paralysis, and another participant did not understand the test method per se. These 4 participants were excluded from the analysis. Muscle endurance in the lower extremities was estimated by the length of time that the participant could hold each lower leg in the horizontal position, with the participant seated in a straight-backed chair (knee extension time). This test estimates the muscle endurance of the quadriceps. Both legs were measured separately. The maximum time was set at 120 s to avoid muscle fatigue and pain that might occur from bearing the leg weight for a longer time.
One participant in the LD + LCT group had right-foot paralysis, and another participant did not understand the test method per se. Two participants in the control group did not understand the test method per se. These 4 participants were excluded from the analysis.
Walking speed. Participants who could walk unaided were asked to walk for 10 m as quickly as they could. Participants who had difficulty in walking unaided were asked to walk for 2.85 m with the support of parallel bars as quickly as they could. Walking speed was calculated from the time and distance completed by each participant.
Two participants in the LD + MCT group could not walk because of muscle weakness, and different evaluation methods were used in another 2 participants to measure walking speed at baseline and after intervention. These evaluation methods included walking with a T-cane (Nissin Medical Industries Co.), circle walker (Matsunaga Manufactory Co.), or Opal (LAC Healthcare). Two participants in the LD + LCT group could not walk because of muscle weakness, a third participant refused to undergo the test, and the abovementioned different evaluation methods were used in another participant to measure walking speed at baseline and after intervention. One participant in the control group had left-foot paralysis, a second participant could not walk because of muscle weakness, and the abovementioned different evaluation methods were used in another 2 participants to measure walking speed at baseline and after intervention. These 12 participants were excluded from the analysis.
Leg open-and-close test (seated). The 10-s leg open-and-close test is used to measure agility without the use of equipment (22) . With the participant sitting in a chair, the number of iterations of opening and closing of the legs during a 10-s period was counted as described previously (22) .
Two participants in the LD + LCT group had right-and left-foot paralysis, respectively, a third participant could not sit, and another participant could not perform this test because of muscle weakness. One participant in the control group had left-foot paralysis, and another 2 participants did not understand the test method per se. These 7 participants were excluded from the analysis.
Respiratory function. To estimate the strength of the respiratory muscles, PEF was measured with the use of a peak flow meter (Scientific Molding Corporation). PEF is the maximum flow generated during expiration performed with maximal force and started after a full inspiration (23) . PEF has been adopted widely to monitor patients with asthma; however, in healthy participants, PEF is determined by lung volume and by the power and coordination of the expiratory muscles (23) . Expiratory muscle strength and PEF are known to decline with aging (24) . Before the measurements, participants were taught how to measure PEF. The best PEF value of 3 attempts was recorded.
Participants whose recorded PEF values were zero (4 participants in the LD + MCT group, 1 participant in the LD + LCT group, and 4 participants in the control group) were excluded from the analysis because it was not clear whether these participants did not understand the method or their PEF value was below the detectable level.
Cognitive function. To estimate cognitive function in participants, 2 different tests were conducted: the Mini-Mental State Examination, in which the participants answer questions themselves (25) , and the Nishimura geriatric rating scale, in which a caregiver or observer answers questions about the participant (26) .
Blood analysis. Venous blood samples were obtained at baseline and after the 3-mo intervention before 0700 after overnight fasting. The postintervention blood sample was obtained the morning after the last dinner of the intervention. Serum was used for measurements of metabolites and enzymes. Missing data (data that could not be collected at baseline and/or after intervention because of difficulty in performing tests) were not included in the analyses. All statistical analyses were performed with the use of the SPSS 20.0 software program (IBM). An a level of 0.05 was used to determine statistical significance.
The percentage of relative change was calculated as (mean of the intervention value -mean of the baseline value)/mean of the baseline value Á 100 (27) . This value then was used to describe the degree of effect.
Results
Participants and compliance. We enrolled 38 participants in the trial (Figure 1 ). Two men dropped out during the study: one from the control group was moved to another nursing home that was suitable for end-of-life care, and the other from the LD + LCT group was moved to a hospital for treatment of dysphagia. Thus, the total number of participants was 36. There were no relevant differences in the groups in the participantsÕ characteristics. Compliance with the supplements was 100%, and no side effects, including diarrhea, were reported.
Dietary intake (excluding supplements and oils). Habitual intake of energy, macronutrients, and some micronutrients at baseline and during the intervention period for each of the groups is shown in Table 3 . The nutrients in the supplements and oils that were administered are not included in this table. No differences in changes in the groups were found with regard to intake of energy, protein, fat, carbohydrate, sodium, or vitamins.
Body weight, BMI, and estimated muscle mass. The differences in changes in the groups in body weight and BMI were significant (P # 0.004) ( Table 4 ). The increases in body weight and BMI were greater in the LD + MCT and LD + LCT groups than in the control group (P < 0.05). After the 3-mo intervention, body weight in the LD + MCT and LD + LCT groups increased by 2.5% (P < 0.01) and 1.8% (P < 0.05), respectively. The increases in body weight and BMI in the intervention groups might have been due to increases in energy intake from the supplements (;7200 kcal over the 3 mo).
The differences in changes in the groups in right TSF, which is a marker of subcutaneous fat tissue mass, were significant (P = 0.001). The increase in right TSF was greater in the control group than in the other 2 groups (P < 0.05). After the 3-mo intervention, the right TSF in the control groups increased by 41.7% (P < 0.001).
The calculated AMA (a marker of skeletal mass) reflected the change in the TSF. Differences in changes in the groups in the right AMA were significant (P = 0.003). The increase in right AMA was greater in the LD + MCT group than in the control group (P < 0.05). After the 3-mo intervention, the right AMA in the LD + LCT and control groups decreased by 6.0% (P < 0.05) and 11.6% (P < 0.01), respectively.
Muscle strength and endurance. The differences in changes in the groups in right-hand grip strength were significant (P = 0.012) ( Table 5 ). The increase in right-hand grip strength was greater in the LD + MCT group than in the control group (P < 0.05). After the 3-mo intervention, the right-hand grip strength in the LD + MCT group increased by 1.2 kg (13.1%) (P < 0.01).
Endurance in the lower extremities was estimated by measuring the length of time for which the participant, in a seated position, could hold each lower leg in the horizontal position. The differences in changes in the groups in right and left knee extension times were significant (P = 0.005 and 0.003, respectively). The length of time that right and left knee extension was maintained was greater in the LD + MCT group than in the LD + LCT group (P < 0.05 in both legs). Locomotive muscle function. The differences in changes in the groups in walking speed were significant by the KruskalWallis test (P = 0.022). The increase in walking speed was greater in the LD + MCT than in the LD + LCT group (P < 0.05). After the 3-mo intervention, the walking speed in the LD + MCT group increased by 12.5% (P < 0.05).
The differences in changes in the groups in the 10-s leg openand-close test also were significant (P < 0.001). The number of iterations in 10 s was greater in the LD + MCT group than in the LD + LCT and control groups (P < 0.05). After the 3-mo intervention, the number of iterations in 10 s in the LD + MCT group increased by 68.2% (P < 0.001).
Respiratory function. The differences in changes in the groups in PEF were significant (P = 0.045). The increase in PEF was greater in the LD + MCT group than in the control group (P < 0.05). After the 3-mo intervention, the PEF per minute in the LD + MCT group increased by 28.2% (P < 0.01).
Blood analysis. Among the items measured in the blood analysis, the differences in changes in the groups were only significant for fasting blood sugar (P = 0.021) (data not shown). The decrease in fasting blood sugar was greater in the control group than in the LD + MCT group (P < 0.05). After the 3-mo intervention, the fasting blood sugar concentration in the control group decreased from 92.4 6 10.5 mg/dL to 82.3 6 7.0 mg/dL (P < 0.01). The reason for the decrease in fasting blood sugar concentration in the control group was not clear.
Discussion
We found that the administration of MCTs (6 g) along with a leucine and cholecalciferol-enriched supplement with dinner every day for 3 mo substantially improved muscle strength and function in frail elderly participants. These favorable effects were not observed in the frail elderly participants who received an energy-matched LCT (6 g) with the leucine and cholecalciferolenriched supplement. These findings appear to indicate that the favorable effects observed in the LD + MCT group were due to the addition of MCT, suggesting that supplementation with a combination of small amounts of leucine-enriched EAAs (40% leucine in 3 g EAAs), cholecalciferol (20 mg, 800 IU), and MCTs (6 g) could achieve synergistic improvement in skeletal muscle function.
As for muscle mass, we could not conclude that supplementation with a combination of leucine-enriched EAAs, cholecalciferol, and MCTs increased muscle mass. Only right AMA was suggested to have been increased, because ANCOVA was significant (P = 0.003). ANCOVA of the left AMA and right and left CC were not significant (P $ 0.26).
Because we could not create an MCTs-only group, it was not clear whether the favorable effects observed in the LD + MCT group occurred because of the combination of the leucine and vitamin-enriched supplement and MCTs (6 g) or were solely due to supplementation with the MCTs. However, in previous metaanalyses, the administration of 9-54 g/d MCTs was not found to be associated with increased muscle mass or function (although it was associated with decreased fat mass) (14, 15) . That the administration of 18-24 g/d MCTs decreased fat-free mass in obese patients in comparison with an olive oil-fed group (28) suggests that the administration of MCTs per se is unlikely to substantially increase muscle mass or muscle function.
A systematic review suggested that supplementation with EAAs, including ;2.5 g leucine and its metabolite b-hydroxy b-methylbutyric acid, achieved some improvement in muscle mass and function; however, the evidence was very limited and inconclusive (6) . In Japanese elderly women aged $75, a supplement of 6 g leucine-rich EAAs/d for 3 mo, which was twice that of our study, did not increase leg muscle mass and walking speed significantly, suggested that a supplement of 3 g leucine-rich EAAs might not improve muscle mass and function (29) .
A meta-analysis that included 3 studies suggested that vitamin D supplementation (800-1000 IU/d) improved balance (sway) and up-and-go test times but did not improve lower extremity strength (30) . These data suggested that 800 IU/d cholecalciferol supplementation per se might not improve muscle function substantially. In agreement with these findings, we did not observe any muscle strength or muscle function improvement (in comparison with the control group) in the LD + LCT group, which received cholecalciferol (20 mg/d, 800 IU/d).
Our speculation on the possible mechanisms behind the increased muscle strength and function observed with the administration of LD + MCT yielded the following hypothesis. The target organs of MCFAs in which increased energy expenditure occurs have been elucidated. In rats, isocaloric feeding with high-fat diets containing MCFAs or long-chain FAs induced a similar degree of hepatic insulin resistance; however, the insulin action was preserved at the concentrations of the lowfat diet-fed controls in the muscle and adipose tissue of the MCFA-fed animals, suggesting that MCTs might increase energy expenditure via the upregulation of mitochondrial oxidative capacity in muscle (31) . In the isolated mitochondria from the skeletal muscle of MCFA-fed mice, respiratory capacity increased (per unit of mitochondria) with an increase in the expression of oxidative proteins (32) . C2C12 myotubes treated with MCFAs displayed less accumulation of fat and increased mitochondrial oxidative capacity in comparison with long-chain FA-treated cells, suggesting a direct effect of MCFAs on skeletal muscle (32) . In mice fed MCTs, there may be an increase in the number of mitochondria and mitochondrial function in the skeletal muscle that occurs via the norepinephrine pathway (33) . This would imply that MCFAs indirectly affect skeletal muscle. Norepinephrine increases peroxisome proliferator-activated receptor g coactivator 1a (PGC-1a)-b and PGC-1a-c mRNA levels in the skeletal muscles, and the increased PGC-1a protein may activate its target mitochondrial proteins and improve muscle function, as is observed in exercise training (34, 35) .
Physical activity might be regulated not only by muscle function but also by brain volume and systemic blood flow (36, 37) . Therefore, it is conceivable that a mixture of MCTs, leucine, and cholecalciferol improves brain function and systemic blood flow by unknown mechanisms. We observed a significant improvement in cognitive function in the LD + MCT group, which was not observed in the LD + LCT and control groups (data not shown). It is possible that increased cognitive function was a cause of the improved muscle function in the LD + MCT group.
The usual daily intake of MCFAs (8:0 + 10:0) is ;100 mg (Table 3) , which is much lower than the 6 g that was administered in the present study. The dose in the present study amounted to a 60-fold increase in MCT intake and a 3-fold increase in vitamin D intake, but only a 30% increase in leucine intake. There were minimal increases in sodium (3%), thiamin (15%), pyridoxine (11%), and cyanocobalamin (9%) in the intervention groups. Therefore, in consideration of the doses that were administered, it is hypothesized that MCTs and cholecalciferol might have been the nutrients that were responsible for the favorable effects. It is possible that cholecalciferol and MCTs increase mRNAs that can induce de novo protein synthesis, which leads to an increase in muscle function (13, 31) . However, it is also conceivable that the simultaneous intake of a small amount of leucine and MCTs can lead to favorable effects.
The present study has several limitations. Because we focused on changes in muscle strength and function, we did not measure muscle size directly by computer tomography or MRI; rather, it was estimated by an anthropometric analysis. The increase in AMA might reflect accumulation of intramuscular lipids rather than an increase in muscle cell number and/or size. A study that uses the needle biopsy method may clarify this issue. Because this study was conducted in a nursing home, the number of participants was small. However, statistically significant improvements in most measurements of muscle strength and function were observed in the LD + MCT group, suggesting that the combined supplementation of MCTs (6 g), leucine-rich amino acids, and cholecalciferol at dinner may be a feasible way to improve muscle strength and function in frail elderly individuals. Although this combination of several nutrients showed promise in the very frail elderly participants in our study, it is not clear whether similar favorable effects would be observed with MCTs only or the combination of 2 nutrients including MCTs, or in other frail populations. Further studies are required to clarify these issues.
